
51.40 Delayed Data As of Aug 19 | ![]() Today’s Change | 28.45 Today|||52-Week Range 66.00 | -1.80% Year-to-Date |
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates Aug 09 / Zacks.com - Paid Partner Content | Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season? Aug 08 / Zacks.com - Paid Partner Content |
Previous close | 50.74 |
Today’s open | 50.17 |
Day’s range | 50.17 - 52.04 |
Volume | 30,666 |
Average volume (3 months) | 814,703 |
Market cap | $5.1B |
Earnings growth (last year) | -8.39% |
Earnings growth (this year) | +8.49% |
Earnings growth (next 5 years) | +2.50% |
Revenue growth (last year) | +267.35% |
P/E ratio | NM |
Price/Sales | 50.75 |
Price/Book | 10.50 |
Next reporting date | November 9, 2022 |
EPS forecast (this quarter) | -$0.80 |
Annual revenue (last year) | $83.8M |
Annual profit (last year) | -$284.1M |
Net profit margin | -339.04% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |